• Multiple Myeloma News
    • Feb 02, 2018

    New Test for Daratumumab (Darzalex) Patients Helps With M-Protein Accuracy

All myeloma patients are familiar with immunofixation tests (typically abbreviated as IFE, for Immmuno Fixation Electrophoresis), which are tests that looks for the presence of monoclonal cells in the blood (serum).

A patient being treated with Darzalex (daratmumab) is infused with monoclonal antibodies and, therefore, the IFE test will show the presence of monoclonals which may lead to an erroneous interpretation of the test results. Some patients think they still have residual disease when in fact they don’t.

This problem has now been solved and gives a little bit of good news for Darzalex patients. The marketer of Darzalex, Janssen Biotech, has collaborated with the company Sebia to develop a new test that mitigates the daratumumab-mediated interference seen with IFE test results.  The US FDA has approved this new test, called Hydrashift 2/4, over the past week for use in multiple myeloma patients being treated with Darzalex.

Ask your doctor about the new test if you are being treated with Darzalex.

About Author

Paul Kleutghen

I've been a primary Plasma Cell Leukemia patient since January 2014. My wife, Vicki, and I have two adult kids and one grandson (the light of our lives). The PCL hasn’t stopped us from doing what we love the most : travel, albeit with some extra precautions these days. I've had a +20 year career in various aspects of the pharma industry and am a retired President/CEO of a generic pharmaceutical company. This photo is hanging on the “Survivor Wall” of the Duke Bone Marrow Transplant Center with the proverbial MM “ monkey on my back”.

MYELOMA CROWD RESEARCH INITIATIVE
$49,561 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

Get Started Today.

Find a Clinical Trial that's Right for You

Thanks to our site sponsors: